BriaCell Therapeutics (BCTX) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 68.9% versus a loss of 69.2%. Metagenomi Therapeutics is the larger company by market cap ($37.5 million vs $34.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | MGX |
|---|---|---|
| Share price | $3.92 | $0.9932 |
| Market cap | $34.10M | $37.52M |
| 1-day change | -2.00% | +0.86% |
| YTD return | -44.87% | -38.69% |
| 1-year return | -69.18% | -68.87% |
| 5-year return | -95.21% | — |
| EPS (TTM) | $-0.92 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.68 | $3.95 |
| 52-week low | $2.60 | $0.96 |
| Distance from 52-week high | -73.30% | -74.86% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +604.79% |
| Average volume | 278.91K | 158.27K |
| Shares outstanding | 8.70M | 37.78M |
| Employees | — | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Healthcare · Biotechnology
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Healthcare · Biotechnology · 113 employees
BCTX vs MGX FAQ
Which is bigger, BriaCell Therapeutics or Metagenomi Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $37.52M compared with $34.10M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or MGX?
MGX returned -68.87% over the past 12 months, compared with -69.18% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.